Health knowledge made personal
Join this community!
› Share page:
Search posts:

UCB Announcement

Posted Jan 30 2010 5:39am

“Following the successful U.S. launches of our core products Cimzia(R) (certolizumab pegol) and Vimpat(R) (lacosamide) and awaiting FDA approval for the U.S. launch of Neupro(R) (rotigotine transdermal patch), we are focusing the resources of the total U.S. organisation and strengthening the foundation for the company’s focus on immunology and neurology. After the exit of the primary care market in most of Western Europe 18 months ago, UCB will now exit the U.S. primary care market, and focus its resources on providing solutions to patients who suffer from severe diseases with Cimzia(R), Vimpat(R) as well as prepare for Neupro(R),” said Roch Doliveux, UCB’s Chief Executive Officer.

For more information on the changes in the focus of UCB and their products, take a look at the FULL ANNOUNCEMENT

Filed under: Drug manufacturers, Neupro Patch, Parkinson's Disease, Restless Leg Syndrome, UCB-Schwarz Pharma Tagged: Neupro, UCB
Post a comment
Write a comment:

Related Searches